## Abstract Sera from 50 patients with Hodgkin's disease, 78 patients with non‐Hodgkin non‐leukemic malignant lymphomas, and 75 patients with different types of solid malignant tumors were investigated for the presence of immune complexes using the (^125^I) C1q‐binding test. All patients were untre
Circulating immune complexes and prognosis in human malignant lymphoma, a prospective study
✍ Scribed by Hans Erik Heier; Tone Ø. Landaas; Per F. Marton
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- French
- Weight
- 723 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Sera from 53 patients with Hodgkin's disease (HD) and 56 patients with non‐Hodgkin malignant lymphoma (NH) were investigated, prior to treatment, for the presence of circulating immune complexes (CIC) by the ^125^l‐C1q‐binding radio‐assay. The patients were then followed for 14–31 months. No significant association was found between the presence of CIC and achievement of complete remission in any of the groups. In none of the groups could a difference be found between the survival rates of patients with and without CIC in their sera prior to treatment. About half of the patients were retested for the presence of CIC after completion of initial therapy. No significant association was found between the presence of post‐treatment CIC and lack of complete remission in any of the patient groups. In the HD group, both pre‐and post‐treatment CIC appeared to be most frequent among patients over 50 years. No such association was found in the NH group.
📜 SIMILAR VOLUMES
Levels of circulating immune complex (clC) and complement split product C3d were studied in 86 patients with breast cancer (BC), 22 patients with benign breast disease (BD), and 72 age-and sex-matched blood-bank donors (NC), using solidphase Clq-protein A RIA, C I q-anti-lgG RIA, anti-C3d anti-lgG R
## Abstract Total hemolytic complement activity (CH 50) and complement component levels were measured in 27 patients with Hodgkin's disease and 31 patients with non‐Hodgkin malignant lymphoma. CH 50 values were higher than normal in almost alt the patients. Increased levels of serum C4, C3 and fact